

Breakthroughs in HCC

Extending Overall Survival Beyond Progression with Regorafenib

An Expert Panel Discussion

Friday, 8 September 2017 | 18:00 – 20:00

IFEMA, Feria de Madrid | Granada Auditorium | Hall 9 | Madrid, Spain



**Prolonging OS in HCC with
Regorafenib: Evidence of Efficacy
and Safety in Second Line**

**Presentation and Panel Discussion:
Switching to Regorafenib Second-line**

Jordi Bruix, MD, PhD
Head of the BCLC (Hepatic Oncology)
Liver Unit, Hospital Clínic
University of Barcelona
IDIBAPS. CIBERehd
Barcelona, Spain



**Presentation and Panel
Discussion: Deciding When
to Start Sorafenib First-line**

Richard Finn, MD
Associate Professor of Medicine
Division of Hematology and Oncology
David Geffen School of Medicine, UCLA
Los Angeles, United States



**Presentation and Panel Discussion:
Defining the Timely Transition from
Liver Directed to Sorafenib Therapy**

Jens Ricke, MD, PhD
Director, Department of Radiology
Ludwig-Maximilians University of Munich
Munich, Germany



**Presentation and Panel Discussion:
Managing Regorafenib Adverse
Events in HCC**

Sandrine Faivre, MD, PhD
Professor of Medical Oncology
Bichat-Beaujon University Hospitals
Paris, France